Harvard Bioscience Sees Q2 Sales $20.500M-$22.500M vs $21.900M Est
Benzinga Newsdesk 5 months ago
NewsGuidance
Harvard Bioscience (NASDAQ:HBIO) sees Q2 sales of $20.500 million-$22.500 million vs $21.900 million analyst estimate.
Harvard Bioscience (NASDAQ:HBIO) sees Q2 sales of $20.500 million-$22.500 million vs $21.900 million analyst estimate.